Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities
Toxicological Sciences · 2025
DOI: 10.1093/toxsci/kfae142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Sean Hammond und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, United Kingdom. Hauptthemen laut MEDLINE: Tolvaptan, Chemical and Drug Induced Liver Injury, Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tolvaptan is a vasopressin V2 receptor antagonist which has proven to be an effective and mostly well-tolerated agent for the treatment of autosomal-dominant polycystic kidney disease. However, its administration is associated with rare but serious idiosyncratic liver injury, which has warranted a black box warning on the drug labels and frequent monitoring of liver blood tests in the clinic. This review outlines mechanistic investigations that have been conducted to date and constructs a working narrative as an explanation for the idiosyncratic drug-induced liver injury (IDILI) events that have occurred thus far. Potential risk factors which may contribute to individual susceptibility to DILI reactions are addressed, and key areas for future investigative/clinical development are highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, United Kingdom.
- ApconiX, Alderley Edge, SK10 4TG, United Kingdom.
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States.
ORCID-Profile: Sean Hammond, Merrie Mosedale, Paul B Watkins
Zitieren
APA
Hammond, S., Meng, X., Barber, J., Mosedale, M., Chadwick, A., Watkins, P. B., & Naisbitt, D. J. (2025). Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae142
Vancouver
Hammond S, Meng X, Barber J, Mosedale M, Chadwick A, Watkins PB, et al. Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfae142
BibTeX
@article{Hammond2025,
author = {Hammond, Sean and Meng, Xiaoli and Barber, Jane and Mosedale, Merrie and Chadwick, Amy and Watkins, Paul B and Naisbitt, Dean J},
title = {Tolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities},
journal = {Toxicological Sciences},
year = {2025},
doi = {10.1093/toxsci/kfae142}
}
EUVIMED